摘要：

脑卒中是临床最常见的脑血管病，严重影响患者生活质量，给家庭和社会带来沉重负担。临床治疗方面，除重组组织型纤溶酶原激活物静脉溶栓外，血管内机械取栓的出现是近年缺血性卒中治疗的重大突破。许多新药业已进入临床试验阶段，为缺血性卒中的治疗带来新的希望。本文拟就我国国民经济和社会发展第十二个五年规划（简称“十二五”）时期取得的缺血性卒中基础与临床研究进展进行概述，包括组学技术、基因治疗、微小RNA 治疗研究和干细胞治疗，特别是干细胞治疗已进入临床试验阶段并展现出良好发展前景。基础研究向临床积极转化为脑血管病的精准治疗提供有价值的信息。

关键词: 卒中, 脑缺血, 中国, 综述

Abstract:

Stroke is the most common cerebrovascular disease worldwide, which seriously affects life quality of survivals and results in huge economic burden of families and society. In terms of clinical treatment for ischemic stroke, apart from thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA), the occurrence and successful application of endovascular thrombectomy in patients of ischemic stroke is a major breakthrough. Meanwhile, many novel clinical drugs for ischemic stroke therapy have entered into clinical trials. Most of basic and clinical researches have showed promising results in ischemic stroke therapy. This review mainly summarizes the progress of research during the period of Twelfth Five-Year Plan for National Economic and Social Development on treatment of ischemic stroke, including omics technologies, gene therapy, microRNA (miRNA) interference and stem cell therapy. Stem cell therapy has shown great potential since many clinical trials have been completed or are ongoing. The development and mutual transformation of basic and clinical research will provide valuable and comprehensive information for the precise treatment of ischemic stroke.

Key words: Stroke, Brain ischemia, China, Review